Effect of Lovastatin on Primary Prevention of Cardiovascular Events in Mild CKD and Kidney Function Loss: A Post Hoc Analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background Chronic kidney disease (CKD) is associated with an increased risk for incident cardiovascular disease (CVD), but the role of statin for the primary prevention of acute cardiovascular events in CKD and the effect of statins on kidney function loss in persons without prevalent CVD have not been studied. Study Design Post-hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. Setting and Participants Multicenter, randomized, double-blind, placebo-controlled trial of 5608 men and 997 women without CVD randomized to lovastatin or placebo. Intervention Placebo or lovastatin 20 mg daily Outcomes and Measurements First major acute cardiovascular event in participants with mild CKD and kidney function loss among persons with or without CKD. Estimated glomerular filtration rate was calculated using the 4-variable Modification of Diet in Renal Disease Study equation. Results At baseline, the mean estimated glomerular filtration rate among CKD participants (n=304) was 53.3 ± 6.0 mL/min/1.73m2. After an average follow-up of 5.3 ± 0.8 years, the incidence of a fatal and non-fatal cardiovascular disease event was lower in CKD participants receiving lovastatin than in those on placebo (adjusted relative risk (RR): 0.31, 95% CI 0.13–0.72; p=0.01). Tests for interaction suggested that the benefit of lovastatin was independent of the presence of CKD. Lovastatin did not reduce the annualized mean decline in estimated glomerular filtration rate (−1.3 ± 0.07 vs. −1.4 ± 0.07 mL/min/1.73m2/year, respectively, p=0.1), the frequency of ≥ 25% decrease in kidney function [adjusted RR: 1.10, 95% CI 0.96 to 1.28, p=0.2] or incident CKD (adjusted RR 1.04, 95% CI 0.86 to 1.27, p=0.6). Limitations Unable to determine cause and duration of kidney disease and information regarding proteinuria was not available. Conclusions Lovastatin is effective for the primary prevention of CVD in CKD, but is not effective in decreasing kidney function loss in persons with no CVD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Coresh, J., Balk, E., Kausz, A. T., Levin, A., Steffes, M. W., Hogg, R. J., Perrone, R. D., Lau, J., & Eknoyan, G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-2-200307150-00013 · Cited by 4,615
Cholesterol and the risk of renal dysfunction in apparently healthy men
Schaeffner, E. S., Kurth, T., Curhan, G. C., Glynn, R. J., Rexrode, K. M., Baigent, C., Buring, J. E., & Gaziano, J. M. (2003) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1482084 · Cited by 442
Tonelli, M., Moy, L., Sacks, F. M., Kiberd, B., Curhan, G., & for the Cholesterol and Recurrent Events (CARE) Trial Investigators (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-2-200301210-00010 · Cited by 278
Cited by
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Santos, C. Y., Snyder, P. J., Wu, W., Zhang, M., Echeverria, A., & Alber, J. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.01.005 · Cited by 431
Palmer, S. C., Craig, J. C., Navaneethan, S. D., Tonelli, M., Pellegrini, F., & Strippoli, G. F. M. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-4-201208210-00007 · Cited by 359
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
Palmer, S. C., Navaneethan, S. D., Craig, J. C., Johnson, D. W., Perkovic, V., Hegbrant, J., & Strippoli, G. F. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007784.pub2 · Cited by 331
Atherosclerosis in Chronic Kidney Disease: More, Less, or Just Different?
Valdivielso, J. M., Rodríguez-Puyol, D., Pascual, J., Barrios, C., Bermúdez-López, M., Sánchez-Niño, M. D., Pérez-Fernández, M., & Ortiz, A. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.312705 · Cited by 305
Metadata
- Authors
- Kendrick, J., Shlipak, M. G., Targher, G., Cook, T., Lindenfeld, J., & Chonchol, M.
- Venue
- American Journal of Kidney Diseases
- Publisher
- Elsevier BV
- Published
- 2010-01
- Volume
- 55
- Issue
- 1
- Pages
- 42-49
- ISSN
- 0272-6386 (ISSN-L)
- OpenAlex
- W2082906144
- Cited by
- 61
- References
- 4
- FWCI
- 6.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.